Biomarker method validation in anticancer drug development
- 1 February 2008
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 153 (4), 646-656
- https://doi.org/10.1038/sj.bjp.0707441
Abstract
Over recent years the role of biomarkers in anticancer drug development has expanded across a spectrum of applications ranging from research tool during early discovery to surrogate endpoint in the clinic. However, in Europe when biomarker measurements are performed on samples collected from subjects entered into clinical trials of new investigational agents, laboratories conducting these analyses become subject to the Clinical Trials Regulations. While these regulations are not specific in their requirements of research laboratories, quality assurance and in particular assay validation are essential. This review, therefore, focuses on a discussion of current thinking in biomarker assay validation. Five categories define the majority of biomarker assays from 'absolute quantitation' to 'categorical'. Validation must therefore take account of both the position of the biomarker in the spectrum towards clinical end point and the level of quantitation inherent in the methodology. Biomarker assay validation should be performed ideally in stages on 'a fit for purpose' basis avoiding unnecessarily dogmatic adherence to rigid guidelines but with careful monitoring of progress at the end of each stage. These principles are illustrated with two specific examples: (a) absolute quantitation of protein biomarkers by mass spectrometry and (b) the M30 and M65 ELISA assays as surrogate end points of cell death.Keywords
This publication has 101 references indexed in Scilit:
- Procedural elements involved in maintaining bioanalytical data integrity for good laboratory practices studies and regulated clinical studiesThe AAPS Journal, 2007
- Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samplesThe AAPS Journal, 2007
- Key elements of bioanalytical method validation for small moleculesThe AAPS Journal, 2007
- Biomarker qualification pilot process at the US Food and Drug AdministrationThe AAPS Journal, 2007
- Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAPBritish Journal of Cancer, 2006
- Drug development in oncology: classical cytotoxics and molecularly targeted agentsBritish Journal of Clinical Pharmacology, 2006
- Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cyclesBritish Journal of Cancer, 2006
- Bead-Based ELISA for Validation of Ovarian Cancer Early Detection MarkersClinical Cancer Research, 2006
- Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging ReagentsMolecular & Cellular Proteomics, 2004
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001